According to the new study , conducted by Coronavirus Vaccine-induced Antibody Titre(COVAT) has found that the seropositivity rates median anti-spike antibody titre was significantly higher in Astra Zeneca’s Covishield as compared to Bharat Biotech’s Covaxin.
“Amongst the 552HCW (325 male, 277 female), 456 and 96 received the first dose of Covishield and Covaxin respectively. Over 79.3 percent showed seropositivity after the first dose. “This ongoing, pan -india , Cross-sectional ,Coronavirus Vaccine-induced Antibody is being conducted amongst HCW, with or without past history of SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four time points between 21 days or more after the first dose to 6 months after the second dose,” the study further said.
Discussion about this post